Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1966 1
1971 1
1972 1
1978 1
1979 1
1982 1
1984 1
1985 4
1986 2
1987 2
1988 2
1990 1
1991 2
1992 2
1993 3
1994 6
1995 5
1996 6
1997 5
1998 4
1999 6
2000 10
2001 11
2002 13
2003 9
2004 6
2005 8
2006 8
2007 7
2008 3
2009 6
2010 8
2011 2
2012 5
2013 5
2014 1
2015 5
2016 4
2017 4
2018 4
2019 7
2020 5
2021 3
2022 3
2023 5
2024 6
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Sworder BJ, et al. Among authors: hosoya h. Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584673 Free PMC article.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. Among authors: hosoya h. J Clin Oncol. 2025 May;43(13):1597-1609. doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18. J Clin Oncol. 2025. PMID: 39965175
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: hosoya h. Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945. Blood. 2025. PMID: 39365257
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees M, Costello P, Vazquez Martinez M, Pasvolsky O, Wagner C, Davis JA, Castaneda Puglianini O, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo R, Freeman C, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa M, Midha S, Alsina M, Sborov D, Patel K, Lin Y, Ferreri C, Gagelmann N, Kumar A, Hansen D, Cowan A, Costa LJ, Merz M, Sidana S. Dhakal B, et al. Among authors: hosoya h. Blood. 2025 Oct 23;146(17):2063-2072. doi: 10.1182/blood.2025029773. Blood. 2025. PMID: 40749169
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. Srinagesh H, et al. Among authors: hosoya h. Blood. 2024 Oct 17;144(16):1689-1698. doi: 10.1182/blood.2024024952. Blood. 2024. PMID: 38968138 Free PMC article. Clinical Trial.
Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H, Sidana S. Hosoya H, et al. Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17. Curr Hematol Malig Rep. 2021. PMID: 33730360 Free PMC article. Review.
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Sidana S, Bankova AK, Hosoya H, Kumar SK, Holmes TH, Tamaresis J, Le A, Muffly LS, Maysel-Auslender S, Johnston L, Arai S, Lowsky R, Meyer E, Rezvani A, Weng WK, Frank MJ, Shiraz P, Maecker HT, Lu Y, Miklos DB, Shizuru JA. Sidana S, et al. Among authors: hosoya h. Blood Cancer J. 2024 Oct 9;14(1):173. doi: 10.1038/s41408-024-01152-1. Blood Cancer J. 2024. PMID: 39384609 Free PMC article. Clinical Trial.
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. Among authors: hosoya h. J Clin Oncol. 2025 Apr 10;43(11):1399. doi: 10.1200/JCO-25-00453. Epub 2025 Mar 7. J Clin Oncol. 2025. PMID: 40053892 No abstract available.
206 results